Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 10
1947 9
1948 3
1951 1
1952 2
1953 1
1957 3
1958 2
1959 1
1961 2
1962 1
1963 1
1964 1
1965 6
1966 1
1967 3
1968 4
1969 8
1970 6
1971 14
1972 6
1973 7
1974 3
1975 5
1976 4
1977 14
1978 12
1979 14
1980 20
1981 14
1982 17
1983 17
1984 14
1985 24
1986 8
1987 12
1988 9
1989 10
1990 12
1991 33
1992 22
1993 28
1994 27
1995 22
1996 37
1997 29
1998 41
1999 54
2000 33
2001 32
2002 50
2003 54
2004 59
2005 87
2006 110
2007 139
2008 159
2009 129
2010 141
2011 154
2012 156
2013 150
2014 168
2015 196
2016 238
2017 208
2018 190
2019 233
2020 264
2021 288
2022 20
Text availability
Article attribute
Article type
Publication date

Search Results

3,510 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. Among authors: agarwal r. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825
Allergic bronchopulmonary aspergillosis.
Agarwal R, Sehgal IS, Dhooria S, Muthu V, Prasad KT, Bal A, Aggarwal AN, Chakrabarti A. Agarwal R, et al. Indian J Med Res. 2020 Jun;151(6):529-549. doi: 10.4103/ijmr.IJMR_1187_19. Indian J Med Res. 2020. PMID: 32719226 Free PMC article. Review.
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Filippatos G, et al. Among authors: agarwal r. Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. Circulation. 2021. PMID: 33198491 Free PMC article. Clinical Trial.
Alport Syndrome Classification and Management.
Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, Toto RD, Chertow GM. Warady BA, et al. Among authors: agarwal r. Kidney Med. 2020 Aug 7;2(5):639-649. doi: 10.1016/j.xkme.2020.05.014. eCollection 2020 Sep-Oct. Kidney Med. 2020. PMID: 33094278 Free PMC article. Review.
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Ruilope LM, et al. Among authors: agarwal r. Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30. Am J Nephrol. 2019. PMID: 31665733 Free PMC article. Clinical Trial.
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Among authors: agarwal r. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Sarraju A, et al. Among authors: agarwal r. Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22. Am Heart J. 2021. PMID: 33358942 Clinical Trial.
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V; CREDENCE Study Investigators. Jardine MJ, et al. Among authors: agarwal r. J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168. J Am Soc Nephrol. 2020. PMID: 32354987 Free PMC article. Clinical Trial.
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V. Bakris G, et al. Among authors: agarwal r. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19. Clin J Am Soc Nephrol. 2020. PMID: 33214158 Free PMC article. Clinical Trial.
3,510 results